| Bioactivity | Quisinostat (JNJ-26481585) is a potent, second-generation and orally active pan-HDAC inhibitor (HDACi), with IC50 values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity[1]. Quisinostat can induce autophagy in neuroblastoma cells[2]. | |||||||||
| Invitro | Quisinostat inhibits HDAC isozymes in vitro[1].Quisinostat (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells[1].Quisinostat has a broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis[1]. Western Blot Analysis[1] Cell Line: | |||||||||
| Name | Quisinostat | |||||||||
| CAS | 875320-29-9 | |||||||||
| Formula | C21H26N6O2 | |||||||||
| Molar Mass | 394.47 | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
Quisinostat
CAS: 875320-29-9 F: C21H26N6O2 W: 394.47
Quisinostat (JNJ-26481585) is a potent, second-generation and orally active pan-HDAC inhibitor (HDACi), with IC50 values
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.